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Wnt signallingIn the last decade, the low-density lipoprotein receptor-related protein 5 (LRP5) gene, coding for a coreceptor
in the canonical Wnt signalling pathway, has been shown to play an important role in regulating bone mass
and to be involved in the pathogenesis of several bone disorders. Here we describe a patient who presented
with a clinical picture of Autosomal Dominant Osteopetrosis type I (ADO I), in whom we could identify the
ﬁrst deletion in the LRP5 gene causing increased bonemass. This mutation caused the in-frame deletion of two
amino acids in the fourth blade of the ﬁrst propeller of the protein, namely the highly conserved glycine at
position 171 and the following glutamate residue. In vitro studies suggested that the pathogenic effect of this
novel mutation could be due to a decreased inhibition ofWnt signalling by the antagonistic proteins sclerostin
and Dickkopf-1, encoded respectively by the SOST and DKK1 genes, in the presence of mutated LRP5. Our




vanhul@ua.ac.be (W. Van Hul),
itasresearch.it,
-NC-ND license.© 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
At the end of the eighties, Bollerslev and Andersen reviewed a
large group of patients affected by Autosomal Dominant Osteopetrosis
(ADO) and, on the basis of radiological and biochemical ﬁndings,
suggested that two different types of ADO existed [1]. More recently
this clinical observation was supported by the results of molecular
investigations in patients, which showed that monoallelic defects
in low-density lipoprotein receptor-related protein 5 (LRP5) gene
caused human ADO I, in which the long bones and the skull are mainly
affected, while mutations in a single allele of the chloride channel 7
(ClCN7) gene were responsible for ADO II, in which an increased rate
of bone fractures is reported. Both LRP5 and ClCN7 proteins are
involved in signalling pathways or cellular processes which are crucialin bone metabolism as demonstrated by the range of bone diseases
arising from differentmutations in either encoding gene. In particular,
biallelic loss of function mutations in LRP5 are responsible for the
autosomal recessive osteoporosis pseudoglioma syndrome (OPPG;
MIM 259770) [2–4]; on the contrary, monoallelic mutations in LRP5,
initially thought to lead to a gain of function of the protein product,
cause a range of phenotypes inherited in an autosomal dominant
way and characterised by increased bone density. These are endosteal
hyperostosis (MIM 144750), osteosclerosis (MIM 144750), domi-
nant osteopetrosis (MIM 607634), van Buchem disease type 2
(VBCH2; MIM 607636) and high bone mass syndrome (HBM; MIM
601884) [4–9]. In addition, studies in different populations have
suggested that LRP5 could be a susceptibility gene for osteoporosis
and fracture risk [10,11].
The speciﬁc clinical picture is strongly related to the LRP5 domain
affected by the mutation. So far, the LRP5 mutations reported to
have an activating effect on Wnt signalling are all missense muta-
tions and clustered in the ﬁrst β-propeller domain of the protein.
Biochemical studies showed that their effect is likely due to a reduced
inhibition of the canonical Wnt pathway by sclerostin and Dickkopf-1
[12–17].
Here we report for the ﬁrst time the identiﬁcation and biochemical
characterization of amutation in the LRP5 gene leading to a two amino
acid deletion in the protein, found in a patient affected by ADO I.
569A. Pangrazio et al. / Bone 49 (2011) 568–571Materials and methods
Case report
The patient herein described is a 56 year old woman of Caucasian
origin, presenting with an ADO I phenotype. The diagnosis was made
on the basis of radiological examinations, performed at menopause
due to generalized bone pain, which she had been suffering from
for many years. Increased bone density mainly involved skull base,
mandible and legs.
No fractures were reported. At 16 years of age, she experienced
complete and sudden blindness of the left eye, whose origin was not
investigated. At 50 years of age, she had an infection of the right ear
and subsequently monolateral impairment of the hearing capacity
arose. At 55 years of age, ophthalmological and audiometric exami-
nations demonstrated reduction of the visual capacity also of the right
eye and worsening of the auditory problems. A CT scan performed
after diagnosis showed a generalised thickening of the skull (Fig. 1)
and restriction of both optical and auditory canals; in addition the
patient referred frequent headaches.
Biochemical studies revealed normal values for serum calcium,
phosphorus, 1,25(OH)2D3 and bone-speciﬁc alkaline phosphatase
(ALP), while PTH was slightly increased.
The patient's father, her daughter and two paternal aunts were all
diagnosed as osteopetrotic on the basis of X-rays, but it has not been
possible to conﬁrm this diagnosis at a molecular level or to perform
further evaluations in any of them.
Samples and mutation analysis
DNA sample from the patient was obtained after receiving
informed consent. Investigation has been approved by the Local
Ethic Committee. Genomic DNA was extracted from PBL by standard
techniques; mutation analysis of the LRP5 gene (AF283320) was
performed as previously described [2].
Expression constructs and in vitro mutagenesis
The deletion found in the proband (g.69547_69552delGGTGAG)
was introduced in untagged full-length human WT LRP5 construct
(obtained from Dr. Matthew Warman, Howard Hughes Medical
Institute, Orthopaedic Research Laboratories, Boston, MA; [2]) usingFig. 1. Axial view of a CT scan of our patient. A generalized thickening of the skull is
evident.the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA) with forward primer 5′-CTGGACAGACTGGACGCCCCGGATTG-3′
and reverse primer 5′-CAATCCGGGGCGTCCAGTCTGTCCAG-3′.
The inserted sequence was veriﬁed for the presence of the
mutation and absence of PCR errors by DNA sequencing.
A mouse Wnt1-V5 expression construct was provided by Dr. Bart
Williams (Van Andel Research Institute, Grand Rapids, MI), a mouse
mesdc-2 expression construct was provided by Dr. Bernadette
Holdener (State University of New York, Stony Brook, NY), a human
DKK1-FLAG expression construct was provided by Dr. Sergei Sokol
(Mount Sinai School of Medicin, New York, NY), a mouse amino
terminal HA-tagged Sost (HA-mSost) expression construct was
obtained from Dr. Matt Warman (Howard Hughes Medical Institute,
Orthopaedic Research Laboratories, USA) and Dr. Bert Vogelstein
(Johns Hopkins University School of Medicine, Baltimore, MD) kindly
provided the Topﬂash Wnt reporter construct (pGL3-OT). The Renilla
Luciferase construct pRL-TK was purchased from Promega Corpora-
tion (Madison, WI) [9].
Cell culture, transfection and luciferase reporter assays
HEK293T and Saos-2 cells were grown in DMEM supplemented
with 10%v/v FBS (Invitrogen, San Diego, CA). Twenty-four hours prior
to transfection, cells were plated at 1.25×105cells/well in 24-well
plates. Cells were transfected using Fugene 6 (Roche Applied Science,
Indianapolis, IN) according to the manufacturer's instructions.
Transfection and luciferase reporter assay were performed as
previously described [9].
Statistical analysis
Data are expressed as mean values±SD. Comparison between
two measurements for a single experiment was performed using a
Student's t-test. Values of pb0.05 were considered signiﬁcant.
Statistical tests were provided by the SPSS 15.0 software package
(IBM Corporation, Somers, NY).
Results
Mutation analysis
Direct sequencing of the region of interest in the LRP5 gene
revealed the presence of an in-frame deletion of six nucleotides
(g.69547_69552delGGTGAG; c.511_516delGGTGAG) in exon 3 in one
allele, corresponding to two amino acid residues (p.Gly171_Glu172-
del), while the other allele was normal (Fig. 2A). As has been reported
for the other high bone mass-causing mutations, this newly identiﬁed
one is also located in the ﬁrst β-propeller domain of the protein,
in its amino terminal, extracellular portion. It involves the glycine
at position 171, which is highly conserved throughout evolution and
between LRP5 and its homologue LRP6, and has been extensively
studied. Interestingly, two missense mutations have been already
reported at this very same position: a p.Gly171Val, found in a family
including phenotypically normal individuals with extremely dense
bones [6] and in another kindred with other clinical features: torus
palatinus and wide, deep mandible, in addition to increased bone
density [5]; and a p.Gly171Arg in a Belgian classical ADO I family [7].
Functional evaluation
To evaluate the functional effect of this new mutation, wild-type
(WT) andmutant (Mut) LRP5 proteins were expressed independently
either in the Saos-2 human osteosarcoma cell line or in HEK293T
cells along with a luciferase reporter construct.
Co-transfection of LRP5 (either WT or Mut) with Wnt1 resulted in
an identical increase in Wnt signalling (Fig. 2B). However, decreased
Fig. 2. A. Sequence information on LRP5 around the new deletion. B. Functional
evaluation of canonical Wnt signalling in Saos-2 cells expressing WT or mutant LRP5.
Fold induction of luciferase reporter activity in cells is normalized to the fold induction
in cells expressing only the Wnt1-V5 expression construct. Bars represent average
values±SD. *: p-valueb0.05.
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with either SOST or DKK1 or a combination of both. Similar results
were obtained in HEK293T cells (data not shown). This suggested that
the in vivo bone phenotype was caused by a decreased ability of
the mutant protein to interact with these two inhibitory molecules.Discussion
In the last two decades, an increasing amount of genetic data has /
INS; clearly demonstrated the role of LRP5 in the regulation of bone
homeostasis. In particular, a limited series of mutations has been
associated with conditions characterised by increased bone density
in humans. In the present work, we report the identiﬁcation of a new
type of mutation in this gene, leading to the in-frame deletion of two
amino acids in the LRP5 protein and resulting in a decreased inhibition
ofWnt signalling by the extracellular antagonists sclerostin and DKK1.
Previously it was shown that a missense mutation of Gly171 results in
impaired binding of both sclerostin and DKK1 [9,14], which allows us
to assume that deletion of this and its ﬂanking amino acid will have a
similar effect. This supports the hypothesis that, besides the third β-
propeller domain of LRP5 [10], the ﬁrst β-propeller domain of the
protein also has a critical role in the binding of sclerostin and DKKs. In
accordancewith the hypothesis raised by Bhat and colleagues [18] the
deletion of the Gly171 and Glu172 residues could alter the three-
dimensional structure of the receptor, thus determining a reduction
in the afﬁnity for its inhibitory ligands. Overall, this disease could
be ascribed to a “gain of function” not with regard to the LRP5 protein
itself, but to the entire signalling pathway, which turns out to be
activated even in the presence of its inhibitory factors.
The proband herein described was a middle-aged woman who
suffered symptoms possibly related to the disease while in her teens,
whereas the diagnosis of osteopetrosis wasmade at menopause when
the clinical symptoms had startedworsening. Her daughter was found
to be osteopetrotic after radiological examination, however she doesnot present any symptoms. Although it is likely that she carries the
same mutation as her mother, conﬁrmation through molecular
analysis was not possible. Our data, together with those already
reported in the literature, conclude that at variance with ADO II, in
which several cases of early onset of the disease are documented
[19,20], ADO I symptoms most frequently arise in adulthood, after the
ﬁrst radiological signs. In addition, ADO I patients do not display
impairment of the haematological compartment, even though the
canonical Wnt signalling is known to play an important role in
haematopoiesis, and rarely present visual deﬁcits, while these defects
can be very evident in some ADO II patients. Interestingly, our patient
did show a complete and abrupt occurrence of blindness at early age,
although the exact cause could not be documented at that time (more
than 40 years ago). All these ﬁndings conﬁrm the original observation
of Bollerslev and Andersen [1] that ADO I and ADO II are two distinct
entities both from a clinical and molecular point of view.
The canonical Wnt signalling has been reported to regulate key
checkpoints in the development of many tissues, and among them,
also in lymphopoiesis [21]. Even though in other forms of osteope-
trosis both primary and secondary immunological defects have
been described, no impairment of the immune system has been
documented in ADO I patients, including ours, possibly due to the high
redundancy of this pathway.
The identiﬁcation of a new type of mutation in the LRP5 gene in
our patient highlights for the ﬁrst time the presence of a molecular
heterogeneity in LRP5-related diseases characterised by high bone
density, which adds to the well-known clinical heterogeneity arising
from mutations in this gene.
Conﬂict of interest
All authors declare no conﬂicts of interest.
Acknowledgments
This work was supported by E-rare project JTC 2007 OSTEOPETR
to AV, Fondazione Cariplo grant to CS, Telethon Foundation (grant
GGP10116) to CS, by Ministero della Salute, convenzione 47 (Role of
new inﬂammatory molecules in pregnancy pathologies and in
maternal neonatal health) to PV, by the European Commission
[HEALTH-F2-2008-201099, TALOS] and by grants from the ‘Fonds
voor Wetenschappelijk Onderzoek’ [FWO, G.0065.10N], from the
Special Research Funds (BOF TOP and NOI) of the University of
Antwerp, all to WVH. EB holds a pre-doctoral specialization scholar-
ship from the “Institute for the Promotion of Innovation through
Science and Technology in Flanders (IWT-Vlaanderen)”.
References
[1] Bollerslev J, Andersen Jr PE. Radiological, biochemical and hereditary evidence of
two types of autosomal dominant osteopetrosis. Bone 1988;9:7–13.
[2] Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL
receptor related protein 5 (LRP5) affects bone accrual and eye development. Cell
2001;107:513–23.
[3] Ai M, Heeger S, Bartels CF, Schelling DK. Osteoporosis-Pseudoglioma Collaborative
Group. Clinical and molecular ﬁndings in osteoporosis-pseudoglioma syndrome.
Am J Hum Genet 2005;77:741–53.
[4] Levasseur R, Lacombe D, De Vernejoul MC. LRP5 mutations in osteoporosis-
pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine
2005;72:207–14.
[5] Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density
due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:
1513–21.
[6] Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, et al. A mutation in
the LDL receptor-related protein 5 gene results in the autosomal dominant high-
bone-mass trait. Am J Hum Genet 2002;70:11–9.
[7] Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, et al. Six
novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in
different conditions with an increased bone density. Am J Hum Genet 2003;72:
763–71.
571A. Pangrazio et al. / Bone 49 (2011) 568–571[8] Rickels MR, Zhang X, Mumm S, Whyte MP. Oropharyngeal skeletal disease
accompanying high bone mass and novel LRP5 mutation. J Bone Miner Res
2005;20:878–85.
[9] Balemans W, Devogelaer JP, Cleiren E, Piters E, Caussin E, Van Hul W. Novel LRP5
missensemutation in a patientwith ahighbonemass phenotype results indecreased
DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res 2007;22:708–16.
[10] Balemans W, Van Hul W. The genetics of low-density lipoprotein receptor-related
protein 5 in bone: a story of extremes. Endocrinology 2007;148:2622–9.
[11] vanMeurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, et al. Large-
scale analysis of association between LRP5 and LRP6 variants and osteoporosis.
JAMA 2008;299:1277–90.
[12] Zhang Y, Wang Y, Li X, Zhang J, Mao J, Li Z, et al. The LRP5 high-bone-mass G171V
mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol 2004;24:4677–84.
[13] Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML. Reduced afﬁnity to and
inhibition by DKK1 form a common mechanism by which high bone mass-
associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell
Biol 2005;25:4946–55.
[14] Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, et al. Bone density
ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate
Wnt activity. J Bone Miner Res 2006;21:1738–49.[15] Semenov MV, He X. LRP5 mutations linked to high bone mass diseases cause
reduced LRP5 binding and inhibition by SOST. J Biol Chem 2006;281:38276–84.
[16] Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, et al. The
binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass
LRP5 mutations. Calcif Tissue Int 2008;82:445–53.
[17] Murrills RJ, Matteo JJ, Bhat BM, Coleburn VE, Allen KM, Chen W, et al. A cell-based
Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1
interaction and highlights differences between wild-type and the high bone mass
mutant LRP5(G171V). J Cell Biochem 2009;108:1066–75.
[18] Bhat BM, Allen KM, LiuW, Graham J, Morales A, Anisowicz A, et al. Structure-based
mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating
Dkk1-mediated inhibition of Wnt signaling. Gene 2007;391:103–12.
[19] Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, et al. Chloride
channel ClCN7 mutations are responsible for severe recessive, dominant, and
intermediate osteopetrosis. J Bone Miner Res 2003;18:1740–7.
[20] Pangrazio A, Pusch M, Caldana E, Frattini A, Lanino E, Tamhankar PM, et al.
Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of
20 novel mutations. Hum Mutat 2010;31:E1071–80.
[21] Staal FJ, Sen JM. The canonical Wnt signaling pathway plays an important role
in lymphopoiesis and hematopoiesis. Eur J Immunol 2008;38:1788–94.
